HLA-haploidentical donor transplantation in severe combined immunodeficiency.
Curative treatment of Severe Combined Immunodeficiency (SCID) by Hematopoietic Cell Transplantation (HCT) remains a challenge, in particular in infants presenting with serious, poorly controllable complications. In the absence of a matched family donor, HLA-haploidentical transplantation from parental donors represents a uniformly and readily available treatment option, offering a high chance to be successful. Concerning outcomes of HCT in SCID, other important parameters beside survival need to be taken into consideration, in particular the stability and robustness of the graft and its function, as well as potential late complications, related either to the disease or to the treatment.
Friedrich
Wilhelm
W
Department of Pediatrics, University of Ulm, Eythstrasse 24, 89075 Ulm, Germany. wilhelm.friedrich@uniklinik-ulm.de
Hönig
Manfred
M
D046148:Donor Selection; D006680:HLA Antigens / Q000235:genetics / Q000276:immunology*; D006239:Haplotypes; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000276:immunology*; D006801:Humans; D010290:Parents; D016511:Severe Combined Immunodeficiency / Q000276:immunology / Q000628:therapy*; D014019:Tissue Donors; D019172:Transplantation Conditioning / Q000379:methods*
D006680:HLA Antigens